share_log

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company

Viveon 健康收購股份有限公司與 Clearday Inc. 宣佈簽署合併並創建一家領先的長壽護理公司的意向書
GlobeNewswire ·  2023/03/01 20:07

Healthcare and med-tech management teams join forces to accelerate longevity-tech solutions into more than 130 million American lives by 2030.

醫療保健和醫療科技管理團隊攜手合作,到 2030 年,將長壽科技解決方案加速到 1.3 億美國人的生活。

Norcross, Georgia, and San Antonio, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company led by principals experienced in healthcare and med-tech innovation, is pleased to announce that it has identified and entered into a letter of intent with a business combination target company, Clearday (OTCQX: CLRD).

喬治亞州諾克羅斯和德州聖安東尼奧,2023 年 3 月 1 日(GLOBE NEWSWIRE)-維維維健康收購公司(紐約證券交易所美國股份有限公司:VHAQ,VHAQW,VHAQW,VHAQU),由醫療保健和醫療技術創新經驗的校長領導的特殊目的收購公司很高興宣布,已確定並訂立目標公司。OTCQX:CLRD)。

Clearday provides a technology platform for the aging population that integrates numerous healthcare innovations into personalized, AI-driven care experiences, which continuously assesses an individual's cognitive and physical capabilities.  The company's customized treatment plans are intended to improve the quality of life for aging and special needs populations. With its autonomous companion robotics and innovative care treatments, Clearday intends to address the $1.4 Trillion burden in annual National Health Expenditures for aging adults.   

Clearday 為老齡人群提供了一個技術平台,將眾多醫療保健創新整合到個人化、AI 驅動的護理體驗中,持續評估個人的認知和身體能力。該公司的定制治療計劃旨在改善老齡化和特殊需求人群的生活質量。憑藉其自主的伴侶機器人技術和創新的護理治療,Clearday 打算解決年齡成人年度全國醫療支出 1.4 萬億美元的負擔。

Company Overview

公司概況

Clearday's () mission is to provide industry-leading longevity care that is more accessible and affordable.  Clearday enables aging individuals, those with special needs, and their families, to optimize their quality of life across the healthcare continuum: at home, in community centers, during medical visits, and at full and part-time care facilities. Clearday's Longevity Care Platform seamlessly integrates numerous health technology innovations into personalized AI-driven care experiences.  The platform continuously assesses an individual's cognitive and physical capabilities to deliver a customized plan.

Clearday()的使命是提供業界領先的長壽護理,更易於訪問和負擔得起。Clearday 使老年人,有特殊需求的人及其家人能夠在整個醫療保健連續體中優化他們的生活質量:在家中,社區中心,醫療訪問期間以及全面和兼職護理設施。Clearday 的長壽護理平台將眾多健康技術創新無縫集成到個性化 AI 驅動的護理體驗中。該平台不斷評估個人的認知和身體能力,以提供定制的計劃。

Globally, the population of individuals over the age of 60 is projected to double by 2050, resulting in nearly 2.1 billion people. In 2035, the US Census Bureau predicts that for the first time, there will be more Americans over the age of 65 than those under 18.  These demographics drive the need for new longevity-tech solutions that provide continuous monitoring, increased engagement, and proactive interventions for older individuals.

在全球範圍內,到 2050 年,60 歲以上的人口預計將增加一倍,導致將近 21 億人口。在 2035 年,美國人口普查局預測,第一次,65 歲以上的美國人將比 18 歲以下的美國人更多。這些人口統計學推動了對新的長壽技術解決方案的需求,為老年人提供持續監控,增加參與度和主動干預措施。

The Clearday Longevity Care Platform delivers solutions through a hub-n-spoke model involving Clearday at Home, Clearday Labs, Clearday Clubs, Clearday Residential, and Clearday Robotics. Together, they offer the industry's leading proactive engagement, intervention, and monitoring solutions for the aging population.

Clearday 長壽護理平台通過中樞正輻模型提供解決方案,該模型涉及 Clearday 家庭,清算實驗室,清算俱樂部,清算日住宅和清算機器人。他們共同為老齡化人口提供業界領先的主動參與、干預和監控解決方案。

Management Comments

管理評論

"Clearday is an ideal merger partner for Viveon Health as it is a transformative healthcare technology company at its inflection point of rapid growth — and addresses an underserved, large, and expanding market," said Jagi Gill, Chief Executive Officer and Chairman of Viveon Health. "As operators ourselves in the healthcare technology space, our hands-on diligence revealed the Clearday team's deliberate expansion and acceleration of their longevity-tech business plan impacting the arc from home to residential care facilities. By leveraging its operational excellence and history in longevity care and bolting on AI-driven solutions to monitor mental and physical health, its solutions can deliver real-time engagement with individuals and their families through robotic-assisted companion care designed to deliver support at any setting. I look forward to working with Jim and the rest of the Clearday team to execute their global sales channel expansion and market development plan poised to deliver growth and shareholder value."

Viveon Health 首席執行官兼董事長 Jagi Gill 表示:「Clearday 是 Viveon Health 理想的合併夥伴,因為它是一家變革性的醫療科技公司,處於快速成長的轉折點,並解決了服務不足、規模龐大且不斷擴張的市場。「作為醫療保健技術領域的運營商,我們的實踐努力揭示了 Clearday 團隊故意擴展和加速其長壽技術業務計劃,從家庭到住宅護理設施都會影響電弧。通過利用其在長壽護理方面的卓越運營和歷史,並在 AI 驅動的解決方案上進行螺紋來監控心理和身體健康,其解決方案可以通過旨在在任何環境中提供支持的機器人輔助伴侶護理,實現與個人及其家人的實時互動。我期待與 Jim 和其他 Clearday 團隊合作,執行他們的全球銷售渠道擴張和市場發展計劃,以實現增長和股東價值。」

James Walesa, CEO and Founder said, "We are thrilled with the opportunity to partner with Viveon and its industry-leading founders, Drs. Jagi Gill and Rom Papadopoulos. Both have decades of experience scaling healthcare technology businesses. Clearday began seeking partners with operational and financial expertise who shared the vision of Clearday's 'Aging in the Right Place.' It has taken longer than I wanted, but today we found the team that combines capital markets experience with healthcare leadership to accelerate Clearday's mission. Their extensive professional contacts and experience will bolster our sales and go-to-market initiatives and generate additional revenue opportunities for the combined companies."

首席執行官兼創始人 James Walisa 表示:「我們很高興有機會與 Viveon 及其業界領先的創始人賈吉爾博士和 Rom Papadopoulos 合作。兩者都有數十年的醫療保健技術業務擴展經驗。Clearday 開始尋找具有運營和財務專業知識的合作夥伴,他們分享了 Clearday「在正確的地方老齡化」的願景。它花費的時間比我想要的要長,但是今天我們發現了將資本市場經驗與醫療保健領導者相結合的團隊,以加快 Clearday 的使命。他們廣泛的專業聯繫和經驗將加強我們的銷售和上市計劃,並為合併後的公司創造額外的收入機會。」

Transaction Overview

交易概覽

Under the terms of the letter of intent, Clearday's existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250 million. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.

根據意向書的條款,Clearday 的現有股權持有人將其股權的 100% 轉換為合併後的上市公司。建議的交易價值結算日為 2.5 億美元。Viveon 預計在執行最終合併協議時公佈有關擬議業務合併的更多詳細信息。

Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

完成與 Clearday 的業務合併,除其他事項外,必須完成盡職調查、就交易提供最終協議的談判、對其中談判的條件的滿意度,以及 Viveon 和 Clearday 董事會和股東批准交易。不能保證將簽訂確定協議,或建議的交易將按照當前預定的條款或時間表完成,或者根本不能保證。

About Clearday, Inc.

關於明日股份有限公司

Clearday is an innovative longevity healthcare technology company with a modern, hopeful vision for making high-quality care solutions more accessible, affordable, and empowering for aging individuals and their families. Clearday has a decades-long experience in non-acute care through its subsidiary Clearday Living, which operates highly-rated residential memory care and adult daycare communities. Its Longevity Care Platform brings Clearday solutions to people wherever they are. Its platform is at the intersection of telehealth, remote monitoring, and patient engagement — all delivered across mobile, wearable, and robotic endpoints in a Software-as-a-Service (SaaS) and Robotics as a Service (RaaS) model. Learn more about Clearday and its pioneering legislative efforts to bring the "Innovative Cognitive Care Act for Veterans" to Congress at .

清算日是一家創新的長壽醫療保健技術公司,擁有現代化、充滿希望的願景,致力於為老齡人士及其家人提供更易於使用、負擔得起的高品質護理解決方案。Clearday 通過其子公司 Clearday Living 在非急性護理方面擁有數十年的經驗,該公司經營高度評價的住宅記憶護理和成人日托社區。其長壽護理平台為無論身在何處的人們提供 Clearday 解決方案。其平台處於遠程醫療、遠端監控和患者參與的交叉點 —— 所有這些都以軟體即服務 (SaaS) 和機器人即服務 (SaaS) 和機器人即服務 (RaaS) 模式在行動裝置、穿戴式裝置和機器人端點上交付。了解有關 Clearday 及其為將「退伍軍人創新認知護理法案」帶到國會的開創性立法工作的更多信息。

About Viveon Health Acquisition Corp.

關於維維康健康收購股份有限公司

Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company's intention to pursue prospective targets that are focused on the healthcare sector in the United States and other developed countries.

Viveon 健康收購股份有限公司是一家空白支票公司,通常也稱為特殊目的收購公司,或 SPAC,為實現合併,股份交換,資產收購,股份購買,重組或與一個或多個業務組合的目的而成立。公司的目標是追求專注於美國和其他發達國家醫療保健行業的潛在目標。

No Offer or Solicitation

沒有要約或招攬

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

本新聞稿不構成就任何證券或與建議業務合併有關的代理,同意或授權的徵求。本新聞稿亦不構成要約出售或徵求購買任何證券的要約,也不得在任何該等司法管轄區的證券法進行註冊或取得資格前,在任何該等司法管轄區的證券法例註冊或資格前違法的任何州或司法管轄區進行任何證券銷售。除非以符合經修訂的 1933 年《證券法》第 10 條規定的招股章程或其豁免,否則不得提出任何證券發售。

Forward-Looking Statements

前瞻性陳述

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project," "outlook" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.  These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Viveon's ability to enter into a definitive agreement or consummate a transaction with the target company. These statements are based on various assumptions and on the current expectations of Viveon's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Viveon and the target company. These forward-looking statements are subject to a number of risks and uncertainties, including: Viveon's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction with the target company; the risk that the approval of the stockholders of Viveon for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction; the amount of redemption requests made by Viveon's stockholders and the amount of funds remaining in Viveon's trust account after satisfaction of such requests; those factors discussed in Viveon's prospectus for its initial public offering dated December 28, 2020, under the heading "Risk Factors," and other documents of Viveon filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Viveon presently does not know or that Viveon currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Viveon's expectations, plans or forecasts of future events and views as of the date hereof. Viveon anticipates that subsequent events and developments will cause Viveon's assessments to change. However, while Viveon may elect to update these forward-looking statements at some point in the future, Viveon specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Viveon's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

本新聞稿中的某些陳述是《1995 年私人證券訴訟改革法》「安全港」條文所指的「前瞻性陳述」。前瞻性陳述可以通過使用諸如「目標,」「相信,」「期望,」「意志,」「應,」「可能」,「預測,」「估計,」「會,」定位,「未來,」「預測,」「意圖,」「計劃,」「項目,」「前景」和「前景」和其他表示未來的趨勢或不表示未來的表達式或其他表達式的趨勢或未來的表達方式歷史事項。這些前瞻性陳述包括 (但不限於) 有關預測、收入的估算和預測、其他財務和績效指標以及市場機會和期望預測的陳述、Viveon 與目標公司簽訂明確協議或完成交易的能力。這些聲明基於各種假設以及目前對 Viveon 管理層的期望,並非對實際績效的預測。這些前瞻性陳述僅供說明用途,並非旨在作為任何投資者依賴,作為擔保,保證,預測或確定事實或概率聲明。實際事件和情況難以預測或不可能預測,並且與假設有所不同。許多實際事件和情況都無法控制 Viveon 和目標公司。這些前瞻性陳述存在一些風險和不明朗因素,包括:Viveon 有能力就擬議的業務合併或與目標公司完成交易簽訂確定協議;未能獲得 Viveon 股東批准潛在交易的風險;未能實現潛在交易的預期效益,包括因為潛在交易而導致的延遲交易;Viveon 股東提出的贖回請求以及在滿意此類要求後,Viveon 信託帳戶中剩餘的資金金額;Viveon 在 2020 年 12 月 28 日首次公開發行的招股說明書中討論的那些因素,標題為「風險因素」,以及 Viveon 向 SEC 提交或將提交的其他文件。如果風險實現或假設證明不正確,實際結果可能與這些前瞻性陳述隱含的結果有很大不同。Viveon 目前不知道或 Viveon 目前認為無關緊要性可能存在其他風險,也可能導致實際結果與前瞻性陳述中包含的結果不同。此外,前瞻性聲明反映了 Viveon 截至本文日期對未來事件和觀點的期望、計劃或預測。Viveon 預計,隨後的事件和發展將導致 Viveon 的評估發生變化。但是,儘管 Viveon 可能會在未來某個時候選擇更新這些前瞻性陳述,但 Viveon 特別聲明不承擔任何這樣做的義務。這些前瞻性陳述不應被視為代表 Viveon 在本新聞稿發布日期之後的任何日期的評估。因此,不應將過度依賴放在前瞻性陳述上。

Contact:

聯繫方式:

Rom Papadopoulos
Viveon Health Acquisition Corp.
Chief Financial Officer
rom@viveonhealth.com
404-861-0839

帕帕多普洛斯公寓
維維康健康收購股份有限公司
首席財務官
rom@viveonhealth.com
404-861-0839

Ginny Connolly
Clearday Inc.
Investor Relations
info@myclearday.com
210-451-0839

金妮·康諾利
清天股份有限公司
投資者關係
info@myclearday.com
210-451-0839


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論